--- title: "Penghua SSE Science and Technology Innovation Board 200 ETF rose over 2.6%, with the innovative drug concept strongly surging" type: "News" locale: "en" url: "https://longbridge.com/en/news/281297308.md" description: "The innovative drug concept performed strongly in the early trading session, influenced by the upcoming American Association for Cancer Research annual meeting. Over 100 Chinese pharmaceutical companies will participate, bringing nearly 400 research results. Guosheng Securities pointed out that the total amount of innovative drug BD licensing will exceed USD 60 billion in the first quarter of 2026, with global cooperation value accelerating to be realized. The Penghua SSE Science and Technology Innovation Board 200 ETF rose by 2.63%, with the latest price reported at 1.52 yuan, closely tracking the SSE Science and Technology Innovation Board 200 Index, which has the top ten weighted stocks accounting for a total of 16.73%" datetime: "2026-04-01T03:09:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281297308.md) - [en](https://longbridge.com/en/news/281297308.md) - [zh-HK](https://longbridge.com/zh-HK/news/281297308.md) --- # Penghua SSE Science and Technology Innovation Board 200 ETF rose over 2.6%, with the innovative drug concept strongly surging The innovative drug concept strengthened in early trading. In terms of news, the American Association for Cancer Research (AACR) Annual Meeting will be held in San Diego, USA, from April 17-22, 2026. It is reported that more than 100 Chinese pharmaceutical companies will showcase nearly 400 research results at AACR this year, covering several current hot targets, including nuclear medicine, DAC, cell therapy, mRNA, and other cutting-edge technologies. Guosheng Securities pointed out that the total amount of innovative drug BD authorization in Q1 2026 exceeded USD 60 billion, and the global cooperation value is accelerating to be realized. In 2025, the overseas authorization of China's innovative drug BD reached a historical high, with a total transaction amount of USD 135.655 billion, an upfront payment of USD 7 billion, and 157 transactions; the heat continued into 2026, and as of March 27, the total amount of external authorization transactions had exceeded USD 60 billion, with the global cooperation value of domestic innovative drugs continuing to be realized. As of 10:35 on April 1, 2026, the Shanghai Stock Exchange Science and Technology Innovation Board 200 Index (000699) rose sharply by 2.88%. Component stocks such as Haitai Xinguang rose by 16.60%, Eddie Pharmaceuticals rose by 16.36%, Bid Pharma rose by 12.74%, and stocks like Haobor and Yuekang Pharmaceuticals also followed suit. The Science and Technology Innovation 200 ETF Penghua (588240) rose by 2.63%, with the latest price reported at CNY 1.52. The Science and Technology Innovation 200 ETF Penghua closely tracks the Shanghai Stock Exchange Science and Technology Innovation Board 200 Index, which selects 200 securities with smaller market capitalization and better liquidity from the Science and Technology Innovation Board of the Shanghai Stock Exchange as samples. The Shanghai Stock Exchange Science and Technology Innovation 200 Index, together with the Shanghai Stock Exchange Science and Technology Innovation Board 50 Component Index and the Shanghai Stock Exchange Science and Technology Innovation Board 100 Index, constitutes the Shanghai Stock Exchange Science and Technology Innovation Board Scale Index Series, reflecting the overall performance of securities of listed companies on the Science and Technology Innovation Board with different market capitalization. Data shows that as of March 31, 2026, the top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board 200 Index (000699) are Changguang Huaxin, Tengjing Technology, Juguang Technology, Dekeli, Jingzhida, Youkede, Jieput, Jiayuan Technology, Juhe Materials, and Weice Technology, with the top ten weighted stocks accounting for a total of 16.73%. The Science and Technology Innovation 200 ETF Penghua (588240) has off-market connections (A: 023926; C: 023927) ### Related Stocks - [000699.CN](https://longbridge.com/en/quote/000699.CN.md) - [588240.CN](https://longbridge.com/en/quote/588240.CN.md) ## Related News & Research - [23:54 ETBD&J Expands Current Pro Bono Offerings with New Pro Bono Division](https://longbridge.com/en/news/286660141.md) - [Peter Menziuso Named EVP and President, BD Interventional | BDX Stock News](https://longbridge.com/en/news/286757706.md) - [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md) - [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md) - [First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial](https://longbridge.com/en/news/286888745.md)